A monoclonal anti CD44 antibody or antigen binding fragment thereof for use in the treatment of a head and neck squamous cell carcinoma (HNSCC) in a mammal wherein said HNSCC is characterized by the expression of CD44. Said monoclonal antibody may be produced by the hybridoma deposited with the ATCC with the accession number PTA 4621 and may be chimeric or humanized versions thereof.
